Trial Profile

A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MERS monoclonal antibody (Primary)
Indications Middle East respiratory syndrome coronavirus
Focus Adverse reactions

Most Recent Events

20 Jun 2024 According to a SAB Biotherapeutics media release, company name changed from SAB Biotherapeutics to SAB BIO.
14 May 2018 Status changed from active, no longer recruiting to completed.
10 Jan 2018 According to an SAB Biotherapeutics media release, John H. Beigel is the principal investigator of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com